Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combination Treatment of Methotrexate, Ibrutinib, and Temozolomide (MIT Regimen) in Patients With Newly Diagnosed Primary CNS Lymphoma

NCT04514393 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT04514393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04514393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combination Treatment of Methotrexate, Ibrutinib, and Temozolomide (MIT Regimen) in Patients With Newly Diagnosed Primary CNS Lymphoma
Lead sponsor
Huiqiang Huang
Phase
Phase 2
Overall status
Unknown status
Start date
October 10, 2020
Completion date
June 1, 2024
Enrollment
33 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma, pcnsl, primary central nervous system lymphoma